Medicure Inc.
Description Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapeutics in Canada, the United States, and Barbados. It markets and sells AGGRASTAT injection (tirofiban hydrochloride), a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. The company researches and develops Tardoxal, which is in Phase II clinical trials for the treatment of tardive dyskinesia/neurological indications. In addition, its novel therapeutics includes a series of small molecule dual acting anticoagulant/antiplatelet compounds to treat venous and arterial thrombosis. The company was founded in 1997 and is headquartered in Winnipeg, Canada. To view the detailed information, you need to SUBSCRIBE with us. |
 |